...a Phase IIb trial for AD. The company gained the compound through its acquisition of Memory Pharmaceuticals Corp....

...Pharmaceuticals AG , Martinsried, Germany Business: Neurology Hired: Stephen Murray as CMO, formerly CMO at Memory Pharmaceuticals Corp....

...Hired: David Lowe as CSO and EVP of R&D, formerly CSO and a director at Memory Pharmaceuticals...

...add-on therapy to Aricept in 360 patients. Roche acquired the compound through its acquisition of Memory Pharmaceuticals Corp....

...evaluating RG4996. The company originally had rights to the compound under a 2003 deal with Memory Pharmaceuticals Corp....

...for $0.61 per share in cash, or about $50 million (see BioCentury, Dec. 8, 2008). Memory Pharmaceuticals Corp....

...companies being scooped up by larger players - such as Roche's $50 million acquisition of Memory Pharmaceuticals...
...and are likely to see more." Last November, Roche announced it would acquire partner Memory Pharmaceuticals Corp....

...rights to MEM 3454 in May 2008, is acquiring Memory (see BioCentury, Dec. 8, 2008). Memory Pharmaceuticals Corp....

...once daily vs. placebo for 7 days in about 16 patients with mild allergic asthma. Memory Pharmaceuticals Corp....

...30, Memory had $14 million in cash and a nine-month operating loss of $33.2 million. Memory Pharmaceuticals Corp....